Genentech, FDA Discussing Herceptin Label Changes To Reflect New PK Data
Executive Summary
Genentech and FDA are discussing updates to Herceptin labeling following the submission of preliminary data suggesting the half-life of trastuzumab is up to five times longer than previously thought.
You may also be interested in...
Genentech Will Focus On Pipeline For Near-Term Growth, CEO Says
Genentech's near-term growth will be based on its product pipeline rather than through acquisitions, CEO Arthur Levinson, PhD, told analysts during the company's fourth quarter earnings call Jan. 16
Genentech Will Focus On Pipeline For Near-Term Growth, CEO Says
Genentech's near-term growth will be based on its product pipeline rather than through acquisitions, CEO Arthur Levinson, PhD, told analysts during the company's fourth quarter earnings call Jan. 16
Genentech Xanelim Therapy Transition Study To Support Product Launch
Genentech plans to generate data on transitioning patients from its psoriasis therapy Xanelim to other products to assist with efalizumab promotions upon approval.